ESPR FY 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

FY 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$78M-65.5% YoY

Gross Profit

$64M81.9% margin

Operating Income

-$227M-289.0% margin

Net Income

-$269M-343.0% margin

EPS (Diluted)

$-11.03

Cash Flow

Operating Cash Flow

-$264M

Free Cash Flow

-$264M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$382M

Total Liabilities

$579M

Stockholders' Equity

-$197M

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$228M	-65.5%
Gross Profit	$64M	$225M	-71.5%
Operating Income	-$227M	-$121M	-86.8%
Net Income	-$269M	-$144M	-87.5%